U.S. markets open in 2 hours 59 minutes

Avid Bioservices, Inc. (CDMO)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
25.65-0.44 (-1.69%)
At close: 4:00PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Price Crosses Moving Average

Price Crosses Moving Average

Previous Close26.09
Open26.07
Bid25.50 x 900
Ask40.00 x 1400
Day's Range25.57 - 26.44
52 Week Range6.61 - 27.02
Volume184,650
Avg. Volume581,819
Market Cap1.567B
Beta (5Y Monthly)2.22
PE Ratio (TTM)450.00
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
-43% Est. Return
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • Avid Bioservices Announces Appointment of Esther M. Alegria, Ph.D., to Board of Directors
    GlobeNewswire

    Avid Bioservices Announces Appointment of Esther M. Alegria, Ph.D., to Board of Directors

    Former SVP of Global Manufacturing at Biogen Has Nearly 30 Years of Biopharmaceutical Industry ExperienceTUSTIN, Calif., July 01, 2021 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO), a dedicated biologics contract development and manufacturing organization (CDMO) working to improve patient lives by providing high quality development and manufacturing services to biotechnology and pharmaceutical companies, today announced the appointment of Esther M. Alegria, Ph.D., as an independent me

  • Avid Bioservices Reports Financial Results for Fourth Quarter and Fiscal Year Ended April 30, 2021 and Recent Developments
    GlobeNewswire

    Avid Bioservices Reports Financial Results for Fourth Quarter and Fiscal Year Ended April 30, 2021 and Recent Developments

    -- Recorded Fourth Quarter Revenue of $27.6 Million and Annual Revenue of $95.9 Million -- -- Achieved Four Consecutive Quarters of Operational Profitability During Fiscal 2021 -- -- Signed Approximately $148 Million in New Business Orders and Achieved a Year-End Backlog of $118 Million During Fiscal 2021 , an 85% and 82% Increase Over Prior Year, Respectively -- -- Raised $138.5 Million Net in Successful Offering of 1.25% Convertible Senior Notes -- -- Project Fiscal 2022 Revenue of $115 to $11

  • Avid Bioservices to Report Financial Results For Quarter and Fiscal Year Ended April 30, 2021 After Market Close on June 29, 2021
    GlobeNewswire

    Avid Bioservices to Report Financial Results For Quarter and Fiscal Year Ended April 30, 2021 After Market Close on June 29, 2021

    TUSTIN, Calif., June 22, 2021 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO), a dedicated biologics contract development and manufacturing organization (CDMO) working to improve patient lives by providing high quality development and manufacturing services to biotechnology and pharmaceutical companies, today announced that it will report financial results for the quarter and fiscal year (FY) ended April 30, 2021 on June 29, 2021 after market close and will host a conference call and we